Sobi to present pooled Gamifant transplant survival analysis in primary HLH at Histiocyte Society 2026

By Public Technologies
  • Swedish Orphan Biovitrum flagged new clinical data for Gamifant in primary HLH for presentation at HS2026 in Rotterdam.
  • Results will be presented in the future, during the Sept. 26-29 meeting, with poster sessions scheduled for Sept. 29.
  • The program highlights pooled evidence on survival outcomes around transplant, positioning Gamifant as a bridge to curative HSCT.
  • Additional analyses point to rapid, durable responses across patient subgroups, including those with prior treatment or CNS involvement.
  • Post-authorization study data in treatment-experienced Chinese patients will add real-world safety and efficacy context relevant to uptake.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Swedish Orphan Biovitrum AB published the original content used to generate this news brief on September 24, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.